Applying a clinical lens to animal models of CAR-T cell therapies
Chimeric antigen receptor (CAR)-T cells have emerged as a promising treatment modality
for various hematologic and solid malignancies over the past decade. Animal models …
for various hematologic and solid malignancies over the past decade. Animal models …
[HTML][HTML] Imaging of T-cells and their responses during anti-cancer immunotherapy
Imaging of T-cells and their responses during anti-cancer immunotherapy - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …
In vivo imaging of nanoparticle-labeled CAR T cells
L Kiru, A Zlitni, AM Tousley, GN Dalton… - Proceedings of the …, 2022 - National Acad Sciences
Metastatic osteosarcoma has a poor prognosis with a 2-y, event-free survival rate of∼ 15 to
20%, highlighting the need for the advancement of efficacious therapeutics. Chimeric …
20%, highlighting the need for the advancement of efficacious therapeutics. Chimeric …
Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
S Park, E Shevlin, Y Vedvyas, M Zaman, S Park… - Scientific reports, 2017 - nature.com
Adoptive transfer of high-affinity chimeric antigen receptor (CAR) T cells targeting
hematological cancers has yielded impressive clinical results. However, safety concerns …
hematological cancers has yielded impressive clinical results. However, safety concerns …
Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
Chimeric antigen receptor (CAR) T cell therapy for hematologic malignancies is fraught with
several unknowns, including number of functional T cells that engage target tumor, durability …
several unknowns, including number of functional T cells that engage target tumor, durability …
Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy
C Barca, CM Griessinger, A Faust, D Depke, M Essler… - Pharmaceuticals, 2021 - mdpi.com
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and
molecular imaging (MI), including positron emission tomography (PET), single-photon …
molecular imaging (MI), including positron emission tomography (PET), single-photon …
Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
Chimeric antigen receptor (CAR) T-cell therapy is one of the most remarkable advances in
cancer therapy in the last several decades. More than 300 adoptive T-cell therapy trials are …
cancer therapy in the last several decades. More than 300 adoptive T-cell therapy trials are …
Bispecific CAR T cells against EpCAM and inducible ICAM-1 overcome antigen heterogeneity and generate superior antitumor responses
Adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated unparalleled
responses in hematologic cancers, yet antigen escape and tumor relapse occur frequently …
responses in hematologic cancers, yet antigen escape and tumor relapse occur frequently …
Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models
The limited number of targetable tumor-specific antigens and the immunosuppressive nature
of the microenvironment within solid malignancies represent major barriers to the success of …
of the microenvironment within solid malignancies represent major barriers to the success of …
Imaging immunity in patients with cancer using positron emission tomography
Immune checkpoint inhibitors and related molecules can achieve tumour regression, and
even prolonged survival, for a subset of cancer patients with an otherwise dire prognosis …
even prolonged survival, for a subset of cancer patients with an otherwise dire prognosis …